Showing 226 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Prostatic Neoplasms, Castration-Resistant Phase 1 Australia
South Africa

Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

Inflammatory Bowel Disease France

Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis Phase 3 Bulgaria
Poland

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma Phase 2 Italy
France
United States
Canada
Spain
Poland
Netherlands
United Kingdom
Belgium
View All

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Gastroenteropancreatic Neuroendocrine Tumors Phase 4 Netherlands
Poland
Italy
United Kingdom
View All

[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake

Neoplasms Phase 1, Phase 2 United Kingdom
United States
Netherlands
Austria
Spain
View All

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Dry Age-related Macular Degeneration Phase 2 United States
France
Spain
Germany
United Kingdom
Australia
View All

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy (SMA) United States
Russian Federation
Japan
Portugal
Ireland
Greece
Taiwan
Korea, Republic of
Israel
View All

LUTATHERA Injection General Use Result Survey

Somatostatin Receptor-positive Neuroendocrine Tumor Japan

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Phase 1 Japan